•By Clinical Dermatology & Formulation Board•5 min clinical read
Formulation & Clinical Summary
Targeting stubborn dark spots: 3% Tranexamic Acid plasmin cascade inhibition, Alpha-Arbutin tyrosinase blocking, and Kojic Acid melanin synthesis disruption.
Melasma and post-inflammatory erythema resist standard brightening creams. Tranexamic acid blocks the plasmin-mediated release of melanocyte-stimulating factors.
1. Multi-Pathway Pigment Disruption
Plasmin Cascade Inhibition: Tranexamic acid prevents UV-induced plasmin activation in keratinocytes, cutting off signals that trigger melanocyte hyperactivity.
Tyrosinase Enzyme Blockade: Alpha-Arbutin and Kojic acid inhibit the rate-limiting enzyme responsible for converting L-tyrosine into dark eumelanin.
Gentle Daily Efficacy: Non-hydroquinone formulation provides long-term daily safety without risk of rebound hyperpigmentation or ochronosis.
🌿
Clinical Dermatology & Formulation Advisory Board
Our editorial board comprises licensed cosmetic chemists, clinical dermatologists, and botanical pharmacognosy researchers auditing active concentrations, molecular delivery systems, and stratum corneum biocompatibility.
Explore Clean Formulations in Our Luxury Boutique
Discover dermatologist-tested serums, lipid repair balms, and antioxidant sunscreens.
